Pharmacodynamics and Proteomic Analysis of Acalabrutinib Therapy: Similarity of On-Target Effects to Ibrutinib and Rationale for Combination Therapy

Acalabrutinib, a highly selective Bruton’s tyrosine kinase inhibitor, is associated with high overall response rates and durable remission in previously treated chronic lymphocytic leukemia (CLL), however, complete remissions were limited. To elucidate on-target and pharmacodynamic effects of acalab...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Leukemia
Asıl Yazarlar: Patel, Viral Kumar, Lamothe, Betty, Ayres, Mary L., Gay, Jason, Cheung, Jean, Balakrishnan, Kumudha, Ivan, Cristina, Morse, Joshua, Nelson, Mark, Keating, Michael J., Wierda, William G., Marszalek, Joseph R., Gandhi, Varsha
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5871548/
https://ncbi.nlm.nih.gov/pubmed/29099493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2017.321
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller